Citations

Showing 10 of 108104 citations.

Secretory Inositol Polyphosphate 4-Phosphatase Protects against Airway Inflammation and Remodeling
Khanna, Kritika , Chaudhuri, Rituparna Kundu , Aich, Jyotirmoi , Pattnaik, Bijay , Panda, Lipsa, Prakash, Y. S. , Mabalirajan, Ulaganathan , Ghosh, Balaram , Agrawal, Anurag , Prakash, Y S , Chaudhuri, Rituparna

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | October 18, 2018 | Volume: 60 | Issue: 4 | Pages: 399-412

10.1165/rcmb.2017-0353oc | PMID 30335467 Get It

Abstract The asthma candidate gene inositol polyphosphate 4-phosphatase type I A (INPP4A) is a lipid phosphatase that negatively regulates the PI3K/Akt pathway. Destabilizing genetic variants of INPP4A increase the risk of asthma, and lung-specific INPP4A knockdown induces asthma-like features. INPP4A is known to localize intracellularly, and its extracellular presence has not been reported yet. Here we show for the first time that INPP4A is secreted by airway epithelial cells and that extracellular INPP4A critically inhibits airway inflammation and remodeling. INPP4A was present in blood and BAL fluid, and this extracellular INPP4A was reduced in patients with asthma and mice with allergic airway inflammation. In both naive mice and mice with allergic airway inflammation, antibody-mediated neutralization of extracellular INPP4A potentiated PI3K/Akt signaling and induced airway hyperresponsiveness, with prominent airway remodeling, subepithelial fibroblast proliferation, and collagen deposition. The link between extracellular INPP4A and fibroblasts was investigated in vitro. Cultured airway epithelial cells secreted enzymatically active INPP4A in extracellular vesicles and in a free form. Extracellular vesicle–mediated transfer of labeled INPP4A, from epithelial cells to fibroblasts, was observed. Inhibition of such transfer by anti-INPP4A antibody increased fibroblast proliferation. We propose that secretory INPP4A is a novel “paracrine” layer of the intricate regulation of lung homeostasis, by which airway epithelium dampens PI3K/Akt signaling in inflammatory cells or local fibroblasts, thereby limiting inflammation and remodeling.
Imaging and diagnostic advances for intracranial meningiomas
Huang, Raymond Y. , Fougère, Christian la , Vogelbaum, Michael A. , Wen, Patrick Y, Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Dunn, Ian F. , Au, Karolyn , Barnhartz-Sloan, Jill, Bi, Wenya Linda, Brastianos, Priscilla K. , Butowski, Nicholas , Carlotti, Carlos Gilberto , Goldbrunner, Roland , Hashizume, Rintaro , Hanemann, C. Oliver , James, David, Jenkinson, Michael D. , Jungk, Christine, Kaufman, Timothy J, Krischek, Boris , Lee, Ian , Liu, Jeff C. , Mamatjan, Yasin , Mansouri, Alireza , Mawrin, Christian , Ng, Ho‐Keung , Pirouzmand, Farhad , Poisson, Laila , Pollo, Bianca , Raleigh, David R. , Sahm, Felix , Saladino, Andrea , Schichor, Christian , Selman, Warren R., Sloan, Andrew E. , Spears, Julian , Snyder, James , Suppiah, Suganth , Tabatabai, Ghazaleh , Tatagiba, Marcos , Tirapelli, Daniela Pretti da Cunha , Tsang, Derek S. , Deimling, Andreas von , Wen, Patrick Y, Walbert, Tobias , Westphal, Manfred , Workewych, Adriana M , Mansouri, Alireza , von Deimling, Andreas , Sahm, Felix , Huang, Raymond , Lee, Ian Y , Bi, Wenya Linda , Griffith, Brent D , Kaufmann, Timothy J. , Schmidt, Nils Ole , Tonn, Joerg-Christian , Wen, Patrick Yung , Cusimano, Michael D. , DiMeco, Francesco , Drummond, Katharine Jann , Galanis, Evanthia , Giannini, Caterina , Herold‐Mende, Christel C. , Horbinski, Craig , Jungk, Christine, Lachance, Daniel Honore , McDermott, Michael , Muñoz, David G. , Noushmehr, Houtan , Perry, Arie , Santarius, Thomas , Schultz, David , Hanemann, C Oliver , Mamatjan, Yasin , Tatagiba, Marcos

Mayo Clinic

Neuro-Oncology | October 18, 2018 | Volume: 21 | Issue: Supplement_1 | Pages: i44-i61

10.1093/neuonc/noy143 | PMID 30649491 Get It

UIAA Medical Commission Recommendations for Mountaineers, Hillwalkers, Trekkers, and Rock and Ice Climbers with Diabetes
Hillebrandt, David , Gurtoo, Anil, Spek, Rianne van der , Wallis, Nikki, Milledge, Jim, Küpper, Thomas , Richards, Paul, Schöffl, Volker , Shah, Pankaj

Mayo Clinic

High Altitude Medicine & Biology | October 18, 2018 | Volume: 24 | Issue: 2 | Pages: 110-126

10.1089/ham.2018.0043 | PMID 30335516 Get It

Hillebrandt, David, Anil Gurtoo, Thomas Kupper, Paul Richards, Volker Schöffl, Pankaj Shah, Rianne van der Spek, Nikki Wallis, and Jim Milledge. UIAA Medical Commission recommendations for mountaineers, hillwalkers, trekkers, and rock and ice climbers with diabetes. High Alt Med Biol . 24: 110–126.—The object of this advice article is not only to give the diabetic mountaineer general guidance but also to inform his or her medical team of practical aspects of care that may not be standard for nonmountaineers. The guidelines are produced in seven sections. The first is an introduction to the guidelines, and the second is an introduction to this medical problem and is designed to be read and understood by diabetic patients and their companions. The third section is for use in an emergency in mountains. The fourth is for rock, ice, and competition climbers operating in a less remote environment. These initial sections are deliberately written in simple language. The fifth and sixth sections are written for clinicians and those with skills to read more technical information, and the seventh looks at modern technology and its pros and cons in diabetes management in a remote area. Sections One and Two could be laminated and carried when in the mountains, giving practical advice.
Th1 cytokines TNF-α and IFN-γ promote corticosteroid resistance in developing human airway smooth muscle
Britt, Rodney D. , Sasse, Sarah K., Prakash, Y. S. , Prakash, Y S , Thompson, Michael A. , Pabelick, Christina M. , Gerber, Anthony N.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | October 18, 2018 | Volume: 316 | Issue: 1 | Pages: L71-L81

10.1152/ajplung.00547.2017 | PMID 30335498 Get It

Corticosteroids (CSs) are commonly used to manage wheezing and asthma in pediatric populations. Although corticosteroids are effective in alleviating airway diseases, some children with more moderate-severe asthma phenotypes show CS resistance and exhibit significant airflow obstruction, persistent inflammation, and more frequent exacerbations. Previous studies have demonstrated that Th1 cytokines, such as TNF-α and IFN-γ, promote CS resistance in adult human airway smooth muscle (ASM). In the present study, using a human fetal ASM cell model, we tested the hypothesis that TNF-α/IFN-γ induces CS resistance. In contrast to TNF-α or IFN-γ alone, the combination of TNF-α/IFN-γ blunted the ability of fluticasone propionate (FP) to reduce expression of the chemokines CCL5 and CXCL10 despite expression of key anti-inflammatory glucocorticoid receptor target genes being largely unaffected by TNF-α/IFN-γ. Expression of the NF-κB subunit p65 and phosphorylation of Stat1 were elevated in cells treated with TNF-α/IFN-γ, an effect that remained in the presence of FP. siRNA knockdown studies demonstrated the effects of TNF-α/IFN-γ on increased p65 are mediated by Stat1, a transcription factor activated by IFN-γ. Expression of TNFAIP3, a negative regulator of NF-κB activity, was not altered by TNF-α/IFN-γ. However, the effects of TNF-α/IFN-γ were partially reduced by overexpression of TNFAIP3 but did not influence p65 expression. Together, these data suggest that IFN-γ augments the effects of TNF-α on chemokines by enhancing expression of key inflammatory pathways in the presence of CS. Interactions between TNF-α- and IFN-γ-mediated pathways may promote inflammation in asthmatic children resistant to CSs.
Cosmetic outcomes and quality of life in children with cardiac implantable electronic devices
Gist, Katja M. , Marino, Bradley S. , Palmer, Claire , Fish, Frank A. , Moore, Jeremy P. , Czosek, Richard J. , Cassedy, Amy , Law, Ian H. , Garnreiter, Jason M., Cannon, Bryan C. , Collins, Kathryn K. , Cannon, Bryan C , Law, Ian H , LaPage, Martin J

Mayo Clinic

Pacing and Clinical Electrophysiology | October 18, 2018 | Volume: 42 | Issue: 1 | Pages: 46-57

10.1111/pace.13522 | PMID 30334588 Get It

AbstractBackgroundAxillary implant location is an alternative implant location in patients for cardiac implantable electronic devices (CIEDs) for the purposes of improved cosmetic outcome. The impact from the patient's perspective is unknown. The purpose of this study was to compare scar perception scores and quality of life (QOL) in pediatric patients with axillary CIED implant location versus the standard infraclavicular approach.MethodsThis is a multicenter prospective study conducted at eight pediatric centers and it includes patients aged from 8 to 18 years with a CIED. Patients with prior sternotomy were excluded. Scar perception and QOL outcomes were compared between the infraclavicular and axillary implant locations.ResultsA total of 141 patients (83 implantable cardioverter defibrillator [ICD]/58 pacemakers) were included, 55 with an axillary device and 86 with an infraclavicular device. Patients with an ICD in the axillary position had better perception of scar appearance and consciousness. Patients in the axillary group reported, on average, a total Pediatric QOL Inventory score that was 6 (1, 11) units higher than the infraclavicular group, after adjusting for sex and race (P = 0.02).ConclusionsQOL is significantly improved in axillary in comparison to the infraclavicular CIED position, regardless of device type. Scar perception is improved in patients with ICD in the axillary position.
Faculty Opinions recommendation of RNA modifications modulate gene expression during development.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 18, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734096430.793551624 Get It

Faculty Opinions recommendation of Developmental enhancers and chromosome topology.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 18, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734096431.793551623 Get It

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
Lambertini, Matteo , Martel, Samuel , Campbell, Christine , Hilbers, Florentine , Schuehly, Uwe, Korde, Larissa A. , Azim, Hatem A. , Cosimo, Serena Di , Tenglin, Richard C., Huober, Jens , Baselga, José , Moreno‐Aspitia, Alvaro , Piccart, Martine , Gelber, Richard D. , Azambuja, Evandro de , Lambertini, Matteo , de Azambuja, Evandro , Campbell, Christine, Guillaume, Sébastien , Ignatiadis, Michail

Mayo Clinic

Cancer | October 18, 2018 | Volume: 125 | Issue: 2 | Pages: 307-316

10.1002/cncr.31784 | PMID 30335191 Get It

Background Limited data exist on the safety of using anti–human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior early breast cancer, with no data in HER2‐positive patients. Methods The Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial and the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial were randomized phase 3 trials for patients with HER2‐positive early breast cancer. In both trials, pregnancy information was prospectively collected. Pregnancy outcomes were compared between patients unintentionally exposed to trastuzumab and/or lapatinib during gestation (the exposed group) and those who became pregnant after trastuzumab and/or lapatinib completion (the unexposed group). In the ALTTO trial, disease‐free survival (DFS) was compared between pregnant patients and those aged 40 years or younger without a subsequent pregnancy via an extended Cox model with time‐varying covariates to account for a guarantee‐time bias. Results Ninety‐two patients (12 in the exposed group and 80 in the unexposed group) had a pregnancy: 7 in the NeoALTTO trial and 85 in the ALTTO trial. Seven patients (58.3%) in the exposed group and 10 patients (12.5%) in the unexposed group opted for an induced abortion; in the unexposed group, 10 patients (12.5%) had a spontaneous abortion. No pregnancy/delivery complications were reported for the remaining cases, who successfully completed their pregnancy, with the exception of 1 fetus with trisomy 21 (Down syndrome). No significant difference in DFS (adjusted hazard ratio, 1.12; 95% confidence interval, 0.52‐2.42) was observed between young patients with a pregnancy (n = 85) and young patients without a pregnancy (n = 1307). Conclusions For patients with HER2‐positive early breast cancer, having a pregnancy after treatment completion appears to be safe without compromising fetal outcome or maternal prognosis.
Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials
Pittayanon, Rapat , Yuan, Yuhong , Bollegala, Natasha , Khanna, Reena , Lacy, Brian E. , Andrews, Christopher N. , Andrews, Christopher N , Leontiadis, Grigorios I. , Moayyedi, Paul

Mayo Clinic

American Journal of Gastroenterology | October 18, 2018 | Volume: 114 | Issue: 2 | Pages: 233-243

10.1038/s41395-018-0258-6 | PMID 30337705 Get It

OBJECTIVES: Prokinetics are recommended for the treatment of functional dyspepsia (FD) but systematic reviews give conflicting results on the efficacy of these agents. We have therefore conducted an updated systematic review to support the 2017 joint ACG/CAG dyspepsia guidelines. METHODS: Electronic databases, including MEDLINE, EMBASE, and CENTRAL, were searched until September 2017 for randomized controlled trials (RCTs) comparing either prokinetics and placebo or two types of prokinetics to improve FD symptoms. The primary outcome was absence or improvement of dyspeptic symptoms at the end of treatment. Double-blind eligibility assessment and data extraction was performed. Pooled risk ratios of symptoms persisting or adverse events occurring, and standardized mean difference of quality-of-life (QoL) scores with 95% CI, using a random effects model, were calculated. Quality of evidence was assessed using GRADE. RESULTS: The search identified 1388 citations; 38 studies in 35 papers were included. Of these, 29 trials comparing prokinetics with placebo were found. There was a statistically significant effect of prokinetic treatment in reducing global symptoms of FD (RR 0.81, 95% CI 0.74 to 0.89; I 2 91%; NNT 7), regardless of FD subtype or ethnicity. When comparing two types of prokinetic, the most commonly used comparator was domperidone. There was no difference in reducing global symptoms (RR 0.94, 95% CI 0.83 to 1.07). QoL was not improved with prokinetic treatment. The adverse events with individual prokinetics were not different from placebo, except for cisapride. The GRADE assessment rated the quality of the evidence in each outcome as very low. CONCLUSIONS: From the current evidence, prokinetics may be effective for the treatment in all subtypes of FD, with very low quality of evidence. There was no difference between prokinetics for dyspeptic symptom improvement. High-quality RCTs with large sample sizes of FD patients are needed to verify the efficacy of prokinetics.
Development of the Painful Periods Screening Tool for endometriosis
DiBenedetti, Dana , Soliman, Ahmed M. , Ervin, Claire , Coddington, Charles C. , Agarwal, Sanjay K. , Surrey, Eric S. , Taylor, Hugh S. , Evans, Emily

Mayo Clinic

Postgraduate Medicine | October 18, 2018 | Volume: 130 | Issue: 8 | Pages: 694-702

10.1080/00325481.2018.1526623 | PMID 30334456 Get It